 July 12, 2013 FDA approved afatinib "multiple recepptor, irreversible TKI" for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutation

BCR-ABL is a constitutively activated tyrosine kinase that is associated with chronic myeloid leukemia.It is formed from a fusion gene when pieces of chromosomes 9 and 22 break off and trade places.The ABL gene from chromosome 9 joins to the BCR gene on chromosome 22, to form the BCR-ABL fusion gene.